_Life

English 한국어 The GLP-1 Revolution & Pharmaceutical Leaders The US wellness industry has evolved into a staggering $2.1 trillion market by 2026, transitioning decisively from traditional fitness models to deep metabolic health and personalized medicine. A primary catalyst for this revolution is the exponential growth of GLP-1 weight loss treatments. Pharmaceutical titans such as Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are at the forefront of this shift. Eli Lilly continues to solidify its market dominance through the success of Mounjaro and Zepbound, alongside its anticipated next-generation oral therapeutics. Concurrently, Novo Nordisk drives innovation with Wegovy and Ozempic, proving pivotal not just in weight reduction, but in mitigating long-term cardiovascular risks. Consumer Wellness & Telehealth Integration In the consumer arena, forward-thinking companies are successfully blending telemedicine with lifestyle m...

Eli Lilly (NYSE: LLY) Investment Analysis English 한국어 Company Overview & Market Position Eli Lilly and Company (NYSE: LLY) has firmly established itself as a titan in the global pharmaceutical industry. With a rich history dating back to 1876, the Indianapolis-based company recently shattered records by becoming the first healthcare corporation to surpass a $1 trillion market capitalization. This monumental achievement is largely driven by its visionary pipeline in metabolic diseases, oncology, and immunology. The GLP-1 Revolution The cornerstone of Eli Lilly's current explosive growth lies in its dual GIP/GLP-1 receptor agonist, tirzepatide—marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The global demand for these therapies has fundamentally reshaped the obesity treatment landscape, creating a robust duopoly alongside Novo Nordisk. In 2025 alone, the combined revenue from these ...